Valuations of Early-Stage Companies and Disruptive Technologies [electronic resource] : How to Value Life Science, Cybersecurity and ICT Start-ups, and their Technologies / by Tiran Rothman.
Valuations of Early-Stage Companies and Disruptive Technologies
Erişim Adresi
ISBN
9783030388478 978-3-030-38847-8
Dil Kodu
İngilizce
Yer Numarası
DK/1832
Yazar
Basım Bildirimi
1st ed. 2020.
Yayın Bilgisi
Cham : Springer International Publishing : Imprint: Palgrave Macmillan, 2020.
Fiziksel Niteleme
XII, 219 p. 11 illus., 5 illus. in color. online resource.
İçindekiler Notu
Part I. A Short Overview of Valuations -- Chapter 1. Introduction -- Chapter 2. Understanding Financial Valuations and Basic Traditional Techniques -- Part II. Overcoming Valuation Hurdles: How to Conduct Valuations Under Unique Circumstances -- Chapter 3. Understanding the Basic Elements of Stockholder Statements and their Use in Valuations -- Chapter 4. Valuation Methods: The First Chicago Venture Method and the Use of Real Options -- Part III. Behavioral Factors: How Psychology Affects Bias in Valuations -- Chapter 5. Introduction to Behavioral Finance -- Chapter 6. An Overview of Investor Behavior in Financial Markets and Psychological Influences on Valuations -- Chapter 7. How to Overcome Investor Behavior and Psychological Influences in Valuations: How to Evaluate a Dream? -- Part IV. An Introduction to Valuations in R&D-Intensive Industries -- Chapter 8. The Pharmaceutical Sector -- Chapter 9. Life Sciences: Disrupting Biologic Drugs Manufacturing -- Chapter 10. An Overview of the Cybersecurity and the Renewable Energy Sectors -- Part V. Actual Valuations -- Chapter 11. Company A: Pharmaceutical / New Compounds -- Chapter 12. Company B: Pharmaceutical / Biologies -- Chapter 13. Company C: Cybersecurity -- Chapter 14. Company D: Renewable Energy -- Chapter 15. Conclusion.
Özet, vb.
This book will serve as a practical guide for entrepreneurs and investors/advisors in constructing and understanding valuations of startups in rapidly shifting industries, including the areas of drug development, medical devices, cyber security, and renewable energy. For large companies, valuation is based on forecasts of free cash flow; in technologically-driven industries, product pipelines can represent a large part of market capitalization. The situation is even more critical for small companies committed to a single idea: all of their value is linked to a single project. Any business transaction or internal proposal to begin or terminate an R&D project in which innovative projects are being valued or exchanged requires a realistic valuation of those projects. Moreover, different projects have very different dynamics. Pharmaceuticals have very large lead times and are dependent on patents as well as out-licensing agreements. In contrast, software develops very quickly, and IP ishard to value. This book will be a guide to building appropriate valuations for companies competing in rapidly shifting industries and offering products under new business models where little precedent exists, taking both financial and behavioral issues into consideration.
Konu
Valuation.
Financial risk management.
New business enterprises.
Venture capital.
Technological innovations.
Computer crimes.
Investment Appraisal.
Risk Management.
Start-Ups and Venture Capital.
Innovation and Technology Management.
Cybercrime.
Financial risk management.
New business enterprises.
Venture capital.
Technological innovations.
Computer crimes.
Investment Appraisal.
Risk Management.
Start-Ups and Venture Capital.
Innovation and Technology Management.
Cybercrime.
